OSE Immunotherapeutics values collaborations and partnerships with pharmaceutical leaders, clinical organizations and academic laboratories as a fundamental element of both its long-term strategy and day-to-day operations.

Sharing knowledge and bringing together key expertise to facilitate the generation of breakthrough discoveries and to ensure the fastest possible delivery of new therapies to patients in need are fundamental to how OSE’s research teams operate.

Having our product development supported by an international network of pharmaceutical, clinical and academic collaborators allows us increased scale and capacity to enhance the value of our assets.

Pharma Partnerships

For OSE Immunotherapeutics, partnerships and out-licensing deals with global pharmaceutical companies represent ways to rapidly advance the clinical development of its product candidates. Selective partnerships represent a key piece of OSE’s business model that can contribute significantly to the cash flow needed to continue discovering and developing new targets and therapeutic candidates. Pharma partnerships can also generate valuable mid- and long-term revenues through milestone payments and royalties.

OSE Immunotherapeutics is actively pursuing a partnership strategy and frequently communicates with potential pharmaceutical partners.

The potential of the Company’s most advanced programs is the basis for strategic partnerships with premier international pharmaceutical companies for the clinical development of key products:

  • Boehringer Ingelheim (April 2018) : A global license and collaboration agreement to develop BI 765063 (OSE-172) in multiple cancer indications.
  • Servier (December 2016): A license option agreement covering development and commercialization of OSE-127 targeting both ulcerative colitis and Sjögren’s syndrome.
  • Veloxis Pharmaceuticals (April 2021): A global license agreement granting Veloxis worldwide rights to develop, manufacture and commercialize FR104 for all transplant indications (in parallel, OSE Immunotherapeutics retains all product rights to develop FR104 in autoimmune diseases).
  • Chong Kun Dang Pharmaceutical Corporation(CKD) (November 2019):  A licensing deal for potential registration and commercialisation of Tedopi® in Korea.

Each of these agreements was comprised of an initial upfront payment as well as milestone payments and royalties on potential future sales.

Together, existing partnerships represent a potential of up to €1.6 billion of revenue for OSE Immunotherapeutics, demonstrating our expertise discovering new targets and therapies and validating the high quality and potential of our drug candidates.

    • OSE-127


    • €10.25 M upfront

      First step option fee, December 2016

    • €30 M

      Second step option fee, Phase 2 completion UC and Sjögren

      Including a €10 M milestone payment received upon exercise of the first option exercised by Servier under the two-step option within the global license agreement (Feb. 2019)

      Including a €5 M milestone payment upon enrollment of 1st patient in the Phase 2a study in Sjögren
      And a €15 M milestone payment upon exercise option completion of both Phase 2 trials, in priority in Sjögren

    • Up to €272 M

      Milestone payments

    • Royalties on sales

    • BI 765063

      Boehringer Ingelheim

    • €15 M upfront

      Upfront payment, April 2018

    • Milestone payments of €15 M

      Upon CTA receipt for the Phase 1 trial and the upcoming first dosing of a patient (S1 2019).

    • Up to €1.1 B

      Milestone payments

    • Royalties on sales

    • FR104

      Veloxis Pharmaceuticals Inc.

    • Upfront €7 M

      Upon signature, April 2021

    • Up to €315 M

    • Milestone payments


      linked to development, registration and commercialization milestones

    • + Tiered royalties on sales

    • Tedopi®


    • €1.2 M upfront and short-term milestones


    • Up to €4.3 M

      In milestone payments + additional royalties on sales and a margin within the transfer price

Up to €1.6 B

Milestone payments

Royalties on sales

Clinical Partnership

A partnership has been put in place with clinical organization:


With the oncology cooperative group GERCOR, a network of 300 cancer centers in France dedicated to clinical trials in solid cancers, to investigate TEDOPI® in pancreatic cancer.

    • Tedopi®


    • Objective

      Phase 2 in pancreatic cancer in monotherapy and in combination with anti-PD-1 Opdivo®

    • Partners

      300 cancer centers in France

    • Next step

      Phase 2 clinical trial ongoing

Academic and Public Partnerships

Since its inception, OSE Immunotherapeutics has collaborated with leading academic teams in the fields of immunology and oncology, notably:

In France

with the INSERM (French National Institute of Health and Medical Research), CNRS (French National Centre for Scientific Research) and Nantes University;

In Europe

with the Children’s Cancer Research Institute of Vienna-Austria, the Biomedical Primate Research Center in the Netherlands or Oxford University in the UK;

In the US

with the University of Maryland in Baltimore or the Ben Towne Center for Childhood Cancer Research in Seattle.

In addition to its wide network of collaborations with top academic centers around the world, OSE Immunotherapeutics is involved in various research and development programs conducted within collaborative consortiums, both funded by partner Bpifrance, a French public investment bank, including:
• EFFIMab, to support OSE-127 development until Phase 2 in collaboration with the INSERM and the Nantes University Hospital;
• EFFI-CLIN, to support BI 765063 development up to the end of Phase 1 in collaboration with the European Center for Transplant and Immunotherapy Sciences (CESTI) and Histalim, a company specialized in immunohistochemistry.

    • OSE-127


    • Objective

      Clinical development until Phase 2

    • Partners

    • Next step

      Phase 2 clinical trial in UC ongoing

    • BI 765063


    • Objective

      Phase 1

    • Partners

    • Next step

      Phase 1 clinical trial ongoing

More information about these agreements can be found in Product section of the website as well as in the media section.